- Home
- ENSC vs PSTV Comparison
ENSC vs PSTV Comparison
Compare ENSC & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- PSTV
- Stock Information
- Founded
- ENSC 2003
- PSTV 1996
- Country
- ENSC United States
- PSTV United States
- Employees
- ENSC N/A
- PSTV N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- PSTV Medical/Dental Instruments
- Sector
- ENSC Health Care
- PSTV Health Care
- Exchange
- ENSC Nasdaq
- PSTV Nasdaq
- Market Cap
- ENSC 7.9M
- PSTV 7.1M
- IPO Year
- ENSC N/A
- PSTV N/A
- Fundamental
- Price
- ENSC $5.40
- PSTV $1.20
- Analyst Decision
- ENSC
- PSTV Strong Buy
- Analyst Count
- ENSC 0
- PSTV 2
- Target Price
- ENSC N/A
- PSTV $13.50
- AVG Volume (30 Days)
- ENSC 26.4K
- PSTV 33.2K
- Earning Date
- ENSC 03-14-2025
- PSTV 03-04-2025
- Dividend Yield
- ENSC N/A
- PSTV N/A
- EPS Growth
- ENSC N/A
- PSTV N/A
- EPS
- ENSC N/A
- PSTV N/A
- Revenue
- ENSC $4,421,404.00
- PSTV $5,725,000.00
- Revenue This Year
- ENSC $89.78
- PSTV $32.12
- Revenue Next Year
- ENSC N/A
- PSTV N/A
- P/E Ratio
- ENSC N/A
- PSTV N/A
- Revenue Growth
- ENSC 40.41
- PSTV 52.63
- 52 Week Low
- ENSC $2.12
- PSTV $0.93
- 52 Week High
- ENSC $14.67
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- ENSC 35.78
- PSTV 48.71
- Support Level
- ENSC $5.34
- PSTV $1.18
- Resistance Level
- ENSC $6.14
- PSTV $1.30
- Average True Range (ATR)
- ENSC 0.43
- PSTV 0.09
- MACD
- ENSC -0.04
- PSTV -0.00
- Stochastic Oscillator
- ENSC 9.49
- PSTV 45.42
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).